BioLine RX (Israel) Top Management

BLRX Stock  ILS 8.10  0.10  1.25%   
BioLine RX employs about 38 people. The company is managed by 11 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 3.45 employees per reported executive. Analysis of BioLine RX's management performance can provide insight into the company performance.
Ella Sorani  President
Vice President - Development
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLine RX. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

BioLine RX Management Team Effectiveness

The company has return on total asset (ROA) of (0.2029) % which means that it has lost $0.2029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3721) %, meaning that it generated substantial loss on money invested by shareholders. BioLine RX's management efficiency ratios could be used to measure how well BioLine RX manages its routine affairs as well as how well it operates its assets and liabilities.

BioLine RX Workforce Comparison

BioLine RX is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 670. BioLine RX holds roughly 38.0 in number of employees claiming about 6% of equities under Health Care industry.

BioLine RX Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. BioLine RX Price Series Summation is a cross summation of BioLine RX price series and its benchmark/peer.

BioLine RX Notable Stakeholders

A BioLine RX stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioLine RX often face trade-offs trying to please all of them. BioLine RX's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioLine RX's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ella SoraniVice President - DevelopmentProfile
CPA CPAChief OfficerProfile
Raziel FriedTreasurer DirectorProfile
Jael MScQA RAProfile
CPA MBAChief OfficerProfile
Holly MBAPres USAProfile
Advocate KotlerGen OfficerProfile
Liron MBADirector DevelProfile
John LaceyHead RelationsProfile
Abi MDChief OfficerProfile
LLB BScHead AdvisorProfile

About BioLine RX Management Performance

The success or failure of an entity such as BioLine RX often depends on how effective the management is. BioLine RX management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioLine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioLine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
Please note, the presentation of BioLine RX's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioLine RX's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioLine RX's management manipulating its earnings.

BioLine RX Workforce Analysis

Traditionally, organizations such as BioLine RX use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioLine RX within its industry.

BioLine RX Manpower Efficiency

Return on BioLine RX Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee711.9K
Net Loss Per Executive2.5M
Working Capital Per Employee1.1M
Working Capital Per Executive3.9M

Complementary Tools for BioLine Stock analysis

When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities